BRIEF-FDA Accepts BLA for BioMarin'' s Cerliponase Alfa for CLN2 Disease

Biomarin Pharmaceutical Inc.

* FDA accepts BLA for BioMarin’s Cerliponase Alfa for CLN2.
disease, kind of Batten illness.

Source text for Eikon:.
Further company coverage:.

( Bengaluru Newsroom: +1 -646 -223 -8780).

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *